Association details:
Evidence Level:
Sensitive: C3 – Early Trials

94: AMELI-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Published date:
AMELI-01 (NCT04106076) is a phase 1 trial evaluating the safety, tolerability, expansion, and persistence of UCART123 given at escalating dose levels after LD with either fludarabine and cyclophosphamide...Evidence of UCART123 activity was observed in 4/16 pts with best overall responses as follows: FC arm (DL2: 1 SD; DL2i: 1 MLFS); FCA arm (DL2: 1 SD and 1 MRD-negative CR)....Overall, these data support the safety and activity of UCART123 after FCA LD in pts with CD123+ R/R AML.
Trial ID: